We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
TetraLogic Initiates Phase 1 Clinical Trial of TL32711 in Patients with Lymphoma
News

TetraLogic Initiates Phase 1 Clinical Trial of TL32711 in Patients with Lymphoma

TetraLogic Initiates Phase 1 Clinical Trial of TL32711 in Patients with Lymphoma
News

TetraLogic Initiates Phase 1 Clinical Trial of TL32711 in Patients with Lymphoma

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "TetraLogic Initiates Phase 1 Clinical Trial of TL32711 in Patients with Lymphoma"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

TetraLogic Pharmaceuticals announced that the Company has completed dosing of the first cohort in a Phase 1 clinical trial of its selective SMAC mimetic, TL32711.

The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will also assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.

“The ability of TL32711 to antagonize Inhibitor of Apoptosis Proteins in a selective manner represents a new broadly applicable approach to treat cancers that are normally resistant to therapies.”

“This is an important milestone for our Company and for cancer patients,” said John M. Gill, President and Chief Executive Officer of TetraLogic Pharmaceuticals. “The ability of TL32711 to antagonize Inhibitor of Apoptosis Proteins in a selective manner represents a new broadly applicable approach to treat cancers that are normally resistant to therapies.”
Advertisement